[Form 4] CITIUS ONCOLOGY, INC. Insider Trading Activity
Rhea-AI Filing Summary
Citius Oncology insider equity grants reported by Chief Medical Officer Myron Czuczman. The filing shows restricted stock awards of 825,000 shares granted on 09/19/2025 that vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds two stock option grants: 400,000 options with a $1.07 exercise price and a 12/12/2034 date shown, and 1,400,000 options with a $2.15 exercise price and a 07/05/2033 date; vesting schedules for the options are described in the filing. All holdings are reported as direct beneficial ownership.
Positive
- None.
Negative
- None.
Insights
TL;DR: Significant equity compensation awarded to the CMO increases his direct stake and aligns incentives with shareholders.
The Form 4 reports a sizable restricted stock award of 825,000 shares and existing/options totaling 1.8 million underlying shares (400,000 and 1,400,000) at exercise prices of $1.07 and $2.15 respectively. Vesting for the restricted shares and options is time-based over three years, conditioned on continuous service. From a capital-structure perspective, these grants increase the insider's undelivered equity stake and create potential future share issuance if options are exercised. No cash purchase price for the restricted shares was reported, and all positions are direct beneficial ownership.
TL;DR: Routine executive equity awards with multi-year vesting; governance implications center on retention incentives and disclosure completeness.
The filing discloses standard employee retention awards: restricted stock vesting in three equal annual tranches and option grants with multi-year vesting schedules tied to continuous service. These are customary forms of executive compensation meant to retain and incentivize management. The Form 4 provides clear vesting schedules and direct ownership designation, satisfying disclosure norms. The filing does not include additional performance conditions or accelerations beyond continuous service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 825,000 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
